US-based laboratory services provider Labcorp has announced the expansion of its precision oncology portfolio to advance patient care and cancer research.
The expansion includes new test offerings for solid tumours, haematologic malignancies, and enhanced biopharma solutions to advance clinical trials and companion diagnostics.
Labcorp is introducing new next-generation sequencing (NGS) panels for myeloid, lymphoid, and pan-haeme indications.
The panels provide broader genomic coverage and actionable insights for patients with haematologic malignancies, aiding oncologists and pathologists in making informed treatment decisions.
In addition, the company is launching a Rapid Acute Myeloid Leukaemia (AML) Panel to enable quicker, informed treatment choices.
Labcorp vice president and oncology medical lead Shakti Ramkissoon said: “Labcorp is committed to serving as the trusted partner for advanced testing at every stage of cancer care.
“Our expanded portfolio and integrated solutions provide our partners with the tools and insights they need to accelerate development programs and drive meaningful improvements in patient outcomes.”
Labcorp is also expanding capabilities to include homologous recombination deficiency (HRD) testing in its OmniSeq INSIGHT pan-solid tumour profiling test.
The addition will assist in identifying ovarian cancer patients who may benefit from targeted therapies like PARP inhibitors or qualify for clinical trials.
Also, the company is expanding FDA-approved companion diagnostics, including HER2 subtype categorisation in breast cancer and the VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer.
Labcorp is expanding its Plasma Focus solid tumour liquid biopsy test to its Geneva, Switzerland, and Shanghai, China sites, to support clinical trials and biopharma collaboration.
The expansion complements the global expansion of Labcorp Tissue Complete, a comprehensive genomic profiling assay for pan-solid tumours.
Together, the assays ensure consistent, high-quality testing across regions, reducing variability and streamlining workflows for biopharma partners.
Labcorp has also launched an advanced digital pathology platform, which uses Leica Biosystems Aperio GT450 scanners and Proscia’s Concentriq LS image management system.
The platform offers a scalable, file-agnostic infrastructure for scanning, archival, and companion diagnostic development.
It enables real-time global peer review and delivers accurate insights with high-volume image analysis and AI-driven interpretation.
